Cerdulatinib

N/A

Report date: 2025/12/15 20:00:38
NME

Base Information

Drug NameCerdulatinib
Drug Alias NameCerdulatinibum赛度替尼舍拉替尼RVT-502PRT-062070 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitorsJanus kinase inhibitors
TargetsJanus kinaseSpleen tyrosine kinase
Therapy Area/IndicationsVitiligoLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPortola Pharmaceuticals IncRoivant Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAciex Therapeutics IncPortola PharmaceuticalsDermavant Sciences Gmbh +[5] 
Active IndicationsN/A
Inactive IndicationsVitiligoLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous +[9] 

Other Information

ATC CodeN/A
Related LinksN/A